Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Buprenorphine/Naloxone Maintenance Therapy: an Observational Retrospective Report on the Effect of Dose on 18 months Retention in an Office-Based Treatment Program.

Parran TV, Mace AG, Dahan YJ, Adelman CA, Kolganov M.

Subst Abuse. 2017 Oct 4;11:1178221817731320. doi: 10.1177/1178221817731320. eCollection 2017.

2.

Sex Differences in Regional Brain Glucose Metabolism Following Opioid Withdrawal and Replacement.

Santoro GC, Carrion J, Patel K, Vilchez C, Veith J, Brodie JD, Dewey SL.

Neuropsychopharmacology. 2017 Aug;42(9):1841-1849. doi: 10.1038/npp.2017.69. Epub 2017 Apr 10.

PMID:
28393895
3.

Probuphine® (buprenorphine implant): a promising candidate in opioid dependence.

Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A.

Ther Adv Psychopharmacol. 2017 Mar;7(3):119-134. doi: 10.1177/2045125316681984. Epub 2016 Dec 19. Review.

4.

Impact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysis.

Dennis BB, Bawor M, Naji L, Chan CK, Varenbut J, Paul J, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, Thabane L, Samaan Z.

Subst Abuse. 2015 Sep 10;9:59-80. doi: 10.4137/SART.S30120. eCollection 2015. Review.

5.

Factors associated with willingness to take extended release naltrexone among injection drug users.

Ahamad K, Milloy MJ, Nguyen P, Uhlmann S, Johnson C, Korthuis TP, Kerr T, Wood E.

Addict Sci Clin Pract. 2015 May 3;10:12. doi: 10.1186/s13722-015-0034-5.

7.

New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.

Soyka M.

Subst Abuse Rehabil. 2015 Jan 6;6:1-14. doi: 10.2147/SAR.S45585. eCollection 2015. Review.

8.

Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.

Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, Hser YI, Wiest K, Cohen AJ, Glick N, Jacobs P, McLaughlin P, Ling W.

J Psychoactive Drugs. 2014 Nov-Dec;46(5):412-26. doi: 10.1080/02791072.2014.921743.

9.

Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Greenwald MK, Comer SD, Fiellin DA.

Drug Alcohol Depend. 2014 Nov 1;144:1-11. doi: 10.1016/j.drugalcdep.2014.07.035. Epub 2014 Aug 19. Review.

10.

Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.

Nielsen S, Hillhouse M, Mooney L, Ang A, Ling W.

J Subst Abuse Treat. 2015 Jan;48(1):70-6. doi: 10.1016/j.jsat.2014.06.006. Epub 2014 Jun 28.

11.

Selective review and commentary on emerging pharmacotherapies for opioid addiction.

Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K.

Subst Abuse Rehabil. 2011 Oct 28;2:181-8. doi: 10.2147/SAR.S22782. eCollection 2011. Review.

12.

Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.

Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH.

Pharmacogenomics J. 2014 Jun;14(3):303-8. doi: 10.1038/tpj.2013.30. Epub 2013 Oct 15.

13.

Comparison of behavioral treatment conditions in buprenorphine maintenance.

Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J.

Addiction. 2013 Oct;108(10):1788-98. doi: 10.1111/add.12266. Epub 2013 Jul 12.

14.

Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD.

Pain. 2013 Aug;154(8):1442-8. doi: 10.1016/j.pain.2013.05.004. Epub 2013 May 7.

15.

An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH.

Neuropsychopharmacology. 2013 Sep;38(10):2003-10. doi: 10.1038/npp.2013.99. Epub 2013 Apr 23. Erratum in: Neuropsychopharmacology. 2014 Mar;39(4):1039.

16.

Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.

Edelman EJ, Fiellin DA.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S86-90. doi: 10.1016/j.amepre.2012.09.035. Review. No abstract available.

17.

A randomized investigation of methadone doses at or over 100 mg/day, combined with contingency management.

Kennedy AP, Phillips KA, Epstein DH, Reamer DA, Schmittner J, Preston KL.

Drug Alcohol Depend. 2013 Jun 1;130(1-3):77-84. doi: 10.1016/j.drugalcdep.2012.10.025. Epub 2012 Nov 26.

18.

Maternal Opioid Treatment: Human Experimental Research (MOTHER)--approach, issues and lessons learned.

Jones HE, Fischer G, Heil SH, Kaltenbach K, Martin PR, Coyle MG, Selby P, Stine SM, O'Grady KE, Arria AM.

Addiction. 2012 Nov;107 Suppl 1:28-35. doi: 10.1111/j.1360-0443.2012.04036.x. Review.

19.

Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial.

Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, Tasissa G, Lokhnygina Y, Leimberger J, Bruce RD, McCarthy J, Wiest K, McLaughlin P, Bilangi R, Cohen A, Woody G, Jacobs P.

Drug Alcohol Depend. 2013 Feb 1;128(1-2):71-6. doi: 10.1016/j.drugalcdep.2012.08.002. Epub 2012 Aug 22.

20.

Maintenance medication for opiate addiction: the foundation of recovery.

Bart G.

J Addict Dis. 2012;31(3):207-25. doi: 10.1080/10550887.2012.694598. Review.

Supplemental Content

Support Center